Faculty
Schulich School of Medicine and Dentistry
Supervisor Name
Dr. Anthony Nichols
Keywords
HNSCC, HPV+, Head and Neck Cancer, Chemotherapy, Cisplatin, UWO23, UWO37, UMSCC47, UPCI:SCC90, 93VU147T
Description
Acquired or innate resistance to chemotherapy poses a significant challenge in the treatment of head and neck squamous cell carcinomas (HNSCC). HNSCCs are often treated with a combination of surgery, radiation and chemotherapy, with cisplatin being a standard-of-care chemotherapy drug. Human Papillomavirus (HPV) associated HNSCCs have better treatment outcomes and prognosis when compared to HPV- HNSCCs. However, a subset (15-20%) of HPV+ patients develop treatment resistant diseases. The purpose of this study is to generate in-vitro models of cisplatin resistance in five HNSCC cell lines. We aim to characterize the generated cells in order to identify target genes that may underlie the molecular basis of cisplatin resistance in HPV+ HNSCC.
Document Type
Poster
Included in
Medical Pathology Commons, Otorhinolaryngologic Diseases Commons, Translational Medical Research Commons
Generating Cisplatin Resistant HPV-positive HNSCC cell lines
Acquired or innate resistance to chemotherapy poses a significant challenge in the treatment of head and neck squamous cell carcinomas (HNSCC). HNSCCs are often treated with a combination of surgery, radiation and chemotherapy, with cisplatin being a standard-of-care chemotherapy drug. Human Papillomavirus (HPV) associated HNSCCs have better treatment outcomes and prognosis when compared to HPV- HNSCCs. However, a subset (15-20%) of HPV+ patients develop treatment resistant diseases. The purpose of this study is to generate in-vitro models of cisplatin resistance in five HNSCC cell lines. We aim to characterize the generated cells in order to identify target genes that may underlie the molecular basis of cisplatin resistance in HPV+ HNSCC.